AbbVie (ABBV) has reported a robust financial performance for Q3 2025, surpassing estimates and showing strong revenue growth despite some margin compression and a $14.5 billion one-off loss. The strong results were driven by the firm's immunology segment, particularly sales of Humira and Rinvoq. However, despite the robust sales, shares of AbbVie have taken a hit and fallen. Furthermore, the halt of the development of its Dragonfly cancer asset is a noteworthy development. The company also faced pressure from President Trump for larger Medicare drug price cuts. Notwithstanding these challenges, AbbVie has raised its EPS guidance for 2025, though it still falls short of consensus. The drugmaker also increased its dividend by 5.5%, which will start in February 2026 and outlined a target to reduce its net leverage ratio. It offered a strong adjusted gross margin projection for FY25 and projected a Q4 revenue that surpasses $16 billion. Numerous investment and asset management firms have increased their stakes in AbbVie. However, shares of AbbVie wobbled after the earnings announcement.
Abbvie ABBV News Analytics from Thu, 11 Sep 2025 07:00:00 GMT to Sat, 01 Nov 2025 18:17:01 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor 5
